03:19 PM EST - Aeterna Zentaris Inc. : announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131. Data showed that AEZS-131 selectively inhibits Erk at low nanomolar (nM) concentrations and induces G1 arrest. Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.03 at $1.71.
